Treat-to-target: Measures

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Yazici, Y ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Measures; Rheumatoid arthritis; Treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; STEROID;

ARTICLE; DISEASE ACTIVITY; LOW DRUG DOSE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84870287839     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
2. GOEKOOP-RUITERMAN YP, DE VRIES-BOU-WSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
3. PINCUS T, SEGURADO OG: Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis. 2006;65:820-2.
4. SAAG KG, TENG GG, PATKAR NM et al.: American College of Rheumatology 2008 Recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
5. SINGH JA, FURST DE, BHARAT A et al.: 2012 Update of the 2008 American College of Rheumatology Recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
6. VAN TUYL LH, BRITSEMMER K, WELLS GA et al:. Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. Ann Rheum Dis 2012;71:33-7.
7. ALETAHA D, SMOLEN J: The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(Suppl. 39):S100-8.
8. STRAND V, COHEN S, CRAWFORD B, SMO-LEN JS, SCOTT DL; LEFLUNOMIDE INVESTI-GATORS GROUPS: Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:640-7.
9. YAZICI Y, CURTIS JR, INCE A et al:. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012;71:198-205.
10. PINCUS T, CHUNG C, SEGURADO OG, AMARA I, KOCH GG: An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006;33:2146-52.
11. PINCUS T, BERGMAN MJ, YAZICI Y, HINES P, RAGHUPATHI K, MACLEAN R: An index of only patient-reported outcome measures, routine assessment of patient index data 3(RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008;47:345-9.
12. PINCUS T, YAZICI Y, BERGMAN M, SWEARINGEN C, HARRINGTON T: A proposed approach to recognise "near-remission" quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAP-ID) score as a guide to a "continuous quality improvement". Clin Exp Rheumatol 2006;24(Suppl.43):S060-73.